Financials
Financial year 2024
Gross margin
€ 436,169
▲ 265% vs 2023
Profit
Growing€ 241,143
▲ 190% vs 2023
Debts
Low€ 611,730
▲ 42% vs 2023
PharmaBXL from Brussel, company number BE0795508480, closed financial year 2024 with a result of € 241,143 after tax. For that financial year PharmaBXL recorded a gross margin of € 436,169 and equity of € 382,053. Compared with financial year 2023, the result moved from € -269,089 to € 241,143. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2025.
What happened at PharmaBXL?
What happened at PharmaBXL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 241,143. filed late Source: NBB ↗
- REMEDIA became a director. NBB
- New establishment in Brussel. KBO
- O2C became a director. NBB
- FILIP GILIAS became a director. NBB
- CERCATROVA became a director. NBB
- PHARMALEGAL became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 269,089 loss in 2023 to € 241,143 profit in 2024.
Best year ever: 2024, with € 241,143 profit.
A new publication or filing at PharmaBXL? We notify you, reason included.
Follow PharmaBXLNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind PharmaBXL are O2C, FILIP GILIAS, REMEDIA, CERCATROVA and PHARMALEGAL. The same people are also behind APOTHEEK GILIAS, Remecare, ZORGPUNT, Lynxcare Clinical Informatics and ASYLIA DIAGNOSTICS.
Directors
According to the 2024 annual accounts
Director · represented by OLBRECHTS OLIVIER
since 2022
since 2022
Director · represented by VAN HAVERBEKE CHARLES
since 2022
Director · represented by DE FEU GEORGES
Also active at: ZORGPUNT, Lynxcare Clinical Informatics, ASYLIA DIAGNOSTICS +3 more
since 2022
Establishments
Establishment units
Physical locations of this company
Zavelput 17
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
Association d'Entraide homophile - Association pour la Défense des Homophiles
PHARMACIE BOTANIQUE
€ 236,541 gross margin · 2023
AMPHIKTION same network
€ 200,476 gross margin · 2024
PharmaPROP.BXL
€ 50,325 gross margin · 2024
PharmaOPS.BXL
€ 596,330 gross margin · 2024
+1 more
Details
- Company number
- 0795.508.480
- VAT number
- BE 0795.508.480
- Registered office
- Zavelput 17, 1000 Brussel
- Names & denominations
- PharmaBXL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 December 2022
- Peppol
- Active · Active since 6 Apr 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Overige zakelijke dienstverlening, neg
Activiteiten van holdings
Groothandel in parfumerieën en cosmetica
Holdings